<DOC>
	<DOCNO>NCT02452255</DOCNO>
	<brief_summary>The propose study test hypothesis Propranolol , fenofibrate fenofibrate plus propranolol therapeutic , physiological , metabolic effect improve clinical outcome , long-term recovery , rehabilitation , QOL burn patient .</brief_summary>
	<brief_title>Fenofibrate Propranolol Burn Patients</brief_title>
	<detailed_description>Determine clinical benefit underlie mechanism whereby metabolic perturbators fenofibrate propranolol impact burn patient outcome . The investigator hypothesize metabolic regulator give one year maintain body mass , improve muscle function increase protein synthesis , augment wound healing , reduce fibrosis , improve cardiovascular function , reduce systemic inflammation , restore insulin sensitivity , decrease liver dysfunction without risk hypoglycemia .</detailed_description>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>0 80 year â‰¥ 20 % TBSA Burn injury Pregnancy History existence preburn injury condition Allergies propranolol fenofibrate Asthma require treatment Congestive heart failure ( measure ejection fraction &lt; 20 % ) Renal hepatic disease Medical condition require glucocorticoid treatment History AIDS , ARC HIV History Cancer within 5 year Decision treat due burn injury severity futility deem clinical team</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>